About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT00415623

A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient

The changes in the trough systolic blood pressure from the baseline were assessed after 8 weeks of double-blind treatment with amlodipine 10 mg or amlodipine 5 mg

Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.•14 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Age

20 - 79 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Untreated Hypertensive Patients: An systolic blood pressure of \>=160 mmHg or diastolic blood pressure \>=100mmHg.
•Treated Hypertensive Patients: An systolic blood pressure of \>=140 mmHg or diastolic blood pressure of \>= 90 mmHg.
•Patients with insufficient response to 5 mg of amlodipine in the screening period:Two successive systolic blood pressure measurements at Visit 4 (Week -2) and Visit 5 (Week 0 = baseline) \>=140 mmHg
•Patients with a screening treatment compliance rate \>= 80%

Exclusion Criteria

•Subjects with secondary hypertension (renal disease, pheochromocytoma, and Cushing's syndrome, etc.), severe hypertension (systolic blood pressure of 180 mmHg or higher, or diastolic blood pressure of 110 mmHg or higher), and malignant hypertension

Related studies

RECRUITINGPhase 3

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029 · Pulmonary Arterial Hypertension

RECRUITINGPhase 3

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

NCT07365332 · Pulmonary Arterial Hypertension

Natural History of Noncirrhotic Portal Hypertension

NCT02417740 · Cystic Fibrosis, Immunologic Deficiency Syndrome, and more

RECRUITINGPhase 1/2

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110 · Healthy Volunteers, Pulmonary Arterial Hypertension

Digital Solutions to Reduce Maternal Morbidity and Mortality in Pregnant Refugee Women

NCT06647511 · Gestational Hypertension

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 11, 2021Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment305

Start dateJan 2007

Last updatedFeb 11, 2021

Condition

Locations shown

Pfizer Investigational Site

Kasuya-gun, Fujuoka

Pfizer Investigational Site

Chikushino-shi, Fukuoka

Pfizer Investigational Site

Kitakyushu, Fukuoka

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 11, 2021Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions